Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Comorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. They also have potential to reduce the initial anxiety that may be caused by early antidepressant treatment due to their inhibitory effect via GABA-A receptor binding. This month's Cochrane Corner review examines the evidence behind combination treatment versus antidepressants alone in major depressive disorder, both in terms of the clinical and neuroscientific context. The review provides evidence that in the first 4 weeks of treatment, additional medication with a benzodiazepine may lead to greater improvements than antidepressant alone in terms of ratings of severity, response rates and remission rates, but not for measures of anxiety.

More information Original publication

DOI

10.1192/bja.2020.17

Type

Journal article

Publication Date

2020-11-01T00:00:00+00:00

Volume

26

Pages

321 - 326

Total pages

5